T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Google Secures Pentagon AI Deal for Classified Projects 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
LA JOLLA, Calif., Feb. 04, 2016 -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, will participate in a fireside chat at 2:15 p.m. ET (11:15 a.m. PT) on Thursday, February 11, 2016 at the 5th Annual Leerink Global Healthcare Conference in New York. The conference will be held at The Waldorf Astoria Hotel in New York City.
A live audio webcast and replay will be available in the Investors section of Kura Oncology's corporate website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. Kura's pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. The company's lead drug candidate is tipifarnib, a farnesyl transferase inhibitor that is currently in three Phase 2 clinical studies: the first study in patients with locally advanced solid tumors that carry HRAS mutations; the second study in patients with peripheral T-cell lymphomas; and the third study, an investigator-sponsored Phase 2 trial, in patients with urothelial carcinoma tumors characterized by HRAS mutations. Kura’s preclinical pipeline includes KO-947, an ERK inhibitor, and a menin-MLL inhibitor program. For additional information about Kura Oncology, please visit www.kuraoncology.com.
CONTACT INFORMATION INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 [email protected] CORPORATE COMMUNICATIONS CONTACT: Mark Corbae Vice President Canale Communications (619) 849 5375 [email protected]
